WuXi Biologics (Cayman) Inc.
WXIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $64,654 | $109,630 | $205,778 | $339,352 |
| - Cash | $8,279 | $9,670 | $6,395 | $9,003 |
| + Debt | $4,940 | $4,561 | $4,422 | $4,295 |
| Enterprise Value | $61,314 | $104,522 | $203,805 | $334,644 |
| Revenue | $18,675 | $17,034 | $15,269 | $10,290 |
| % Growth | 9.6% | 11.6% | 48.4% | – |
| Gross Profit | $7,651 | $6,828 | $6,724 | $4,829 |
| % Margin | 41% | 40.1% | 44% | 46.9% |
| EBITDA | $6,429 | $5,502 | $6,223 | $4,514 |
| % Margin | 34.4% | 32.3% | 40.8% | 43.9% |
| Net Income | $3,356 | $3,400 | $4,420 | $3,388 |
| % Margin | 18% | 20% | 29% | 32.9% |
| EPS Diluted | 0.78 | 0.77 | 1.01 | 0.77 |
| % Growth | 1.3% | -23.8% | 31.2% | – |
| Operating Cash Flow | $5,217 | $4,668 | $5,542 | $3,431 |
| Capital Expenditures | -$3,930 | -$4,231 | -$5,868 | -$6,523 |
| Free Cash Flow | $1,288 | $437 | -$327 | -$3,092 |